blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3265452

EP3265452 - PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.01.2021
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  31.01.2020
FormerGrant of patent is intended
Status updated on  18.11.2018
FormerRequest for examination was made
Status updated on  08.12.2017
FormerThe international publication has been made
Status updated on  24.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): AL, MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Neuprozyme Therapeutics ApS
Agern Allé 3
2970 Hørsholm / DK
[2020/09]
Former [2018/02]For all designated states
ProZymex A/S
Agern Allé 3
2970 Hørsholm / DK
Inventor(s)01 / LAURITZEN, Conni
Axelhøj 59
2610 Rødovre / DK
02 / PEDERSEN, John
Skovparken 8
2990 Nivå / DK
 [2018/02]
Representative(s)Inspicos P/S
Agern Allé 24
2970 Hørsholm / DK
[N/P]
Former [2018/02]Inspicos P/S
Kogle Allé 2
2970 Hørsholm / DK
Application number, filing date16707819.504.03.2016
[2018/02]
WO2016EP54674
Priority number, dateEP2015015781105.03.2015         Original published format: EP 15157811
[2018/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016139351
Date:09.09.2016
Language:EN
[2016/36]
Type: A1 Application with search report 
No.:EP3265452
Date:10.01.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 09.09.2016 takes the place of the publication of the European patent application.
[2018/02]
Type: B1 Patent specification 
No.:EP3265452
Date:04.03.2020
Language:EN
[2020/10]
Search report(s)International search report - published on:EP09.09.2016
ClassificationIPC:C07D309/14, A61K31/496, A61P11/06, A61P11/00, A61P37/00, A61P25/28, A61P17/06, A61P31/12, A61P9/04, A61P9/10, A61P31/02, A61P19/06
[2018/02]
CPC:
C07D405/12 (EP,US); A61P1/04 (EP); A61P11/00 (EP);
A61P11/06 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P19/06 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P31/02 (EP); A61P31/04 (EP);
A61P31/12 (EP); A61P33/06 (EP); A61P37/00 (EP);
A61P43/00 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/10 (EP); C07D309/14 (EP,US); Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/02]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PEPTIDYLNITRIL-VERBINDUNGEN ALS PEPTIDYLPEPTIDASE-I-INHIBITOREN[2018/47]
English:PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS[2018/02]
French:COMPOSÉS PEPTIDYLNITRILE EN TANT QU'INHIBITEURS DE LA DIPEPTIDYLE PEPTIDASE I[2018/47]
Former [2018/02]PEPTIDYLNITRILVERBINDUNGEN ALS DIPEPTIDYLPEPTIDASE-I-HEMMER
Former [2018/02]COMPOSÉS DE PEPTIDYL-NITRILE EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL-PEPTIDASE I
Entry into regional phase05.10.2017National basic fee paid 
05.10.2017Designation fee(s) paid 
05.10.2017Examination fee paid 
Examination procedure31.12.2016Request for preliminary examination filed
International Preliminary Examining Authority: EP
22.09.2017Date on which the examining division has become responsible
05.10.2017Examination requested  [2018/02]
24.05.2018Amendment by applicant (claims and/or description)
19.11.2018Communication of intention to grant the patent
29.03.2019Fee for grant paid
29.03.2019Fee for publishing/printing paid
29.03.2019Receipt of the translation of the claim(s)
Opposition(s)07.12.2020No opposition filed within time limit [2021/06]
Fees paidRenewal fee
22.03.2018Renewal fee patent year 03
20.03.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.03.2016
AL04.03.2020
AT04.03.2020
CY04.03.2020
CZ04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LU04.03.2020
LV04.03.2020
MC04.03.2020
MK04.03.2020
MT04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
[2022/31]
Former [2022/27]HU04.03.2016
AT04.03.2020
CY04.03.2020
CZ04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LU04.03.2020
LV04.03.2020
MC04.03.2020
MT04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
TR04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2021/11]AT04.03.2020
CZ04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LU04.03.2020
LV04.03.2020
MC04.03.2020
PL04.03.2020
RO04.03.2020
RS04.03.2020
SI04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2021/04]CZ04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LU04.03.2020
LV04.03.2020
MC04.03.2020
RO04.03.2020
RS04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/50]CZ04.03.2020
EE04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
RO04.03.2020
RS04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/49]CZ04.03.2020
ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
RO04.03.2020
RS04.03.2020
SK04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/48]ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
RO04.03.2020
RS04.03.2020
SM04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
PT29.07.2020
Former [2020/47]ES04.03.2020
FI04.03.2020
HR04.03.2020
LT04.03.2020
LV04.03.2020
RS04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/46]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
BG04.06.2020
GR05.06.2020
IS04.07.2020
Former [2020/39]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
BG04.06.2020
GR05.06.2020
Former [2020/38]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
GR05.06.2020
Former [2020/37]FI04.03.2020
HR04.03.2020
LV04.03.2020
RS04.03.2020
Former [2020/35]FI04.03.2020
Cited inInternational search[YD]WO2010128324  (ASTRAZENECA AB [SE], et al) [YD] 1-15 * claims 1, 11-13 * * example 25 * * page 149 - page 150; table 1 *;
 [YD]WO2012119941  (PROZYMEX AS [DK], et al) [YD] 1-15 * claims 1, 25-27 * * page 4, line 23 - line 28 * * 4th compound on page 39, 2nd compound on page 41, 2nd compound on page 43, 3rd compound on page 53 *;
 [A]WO2014140075  (BOEHRINGER INGELHEIM INT [DE]) [A] 1-15 * claims 1, 17-19 ** page 284; compound 185 *
by applicantWO2009074829
 WO2010128324
 WO2010142985
 WO2012119941
 WO2012130299
 WO2013041497
 WO2015004677
    - ADKISON ET AL., J. CLIN. INVEST, (2002), vol. 109, pages 363 - 271
    - PHAM ET AL., J. IMMUNOL, (2004), vol. 173, pages 7277 - 7281
    - NATHALIE MÉTHOT; DANIEL GUAY; JOEL RUBIN; DIANE ETHIER; KAREN ORTEGA; SIMON WONG; DENIS NORMANDIN; CHRISTIAN BEAULIEU, T; JAGADEE, "In Vivo Inhibition of Serine protease Processing Requires a High Fractional Inhibition of Cathepsin C", MOL PHARMACOL, (2008), vol. 73, pages 1857 - 1865, XP002609243
    - NATHALIE METHOT; JOEL RUBIN; DANIEL GUAY; CHRISTIAN BEAULIEU; DIANE ETHIER T; JAGADEESWAR REDDY; DENIS RIENDEAU; M. DAVID PERCIVAL, "Inhibition of the Activation of Multiple Serine proteases with a Cathepsin C Inhibitor Requires Sustained Exposure to Prevent Pro-enzyme", PROCESSING J. BIOL. CHEM., (20070720), vol. 282, no. 29, doi:doi:10.1074/jbc.M702615200, pages 20836 - 20846, XP009105570

DOI:   http://dx.doi.org/10.1074/jbc.M702615200
    - JON BONDEBJERG; HENRIK FUGLSANG; KIRSTEN ROSENDAL VALEUR; JOHN PEDERSEN; LARS NAERUM, "Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2006), vol. 16, doi:doi:10.1016/j.bmcl.2006.01.102, pages 3614 - 3617, XP028803197

DOI:   http://dx.doi.org/10.1016/j.bmcl.2006.01.102
    - BERGE, S. M. ET AL., "Pharmaceutical salts", J. PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY
    - The Handbook of Pharmaceutical Additives, GOWER PUBLISHING LIMITED
    - The Handbook of Pharmaceutical Excipients, AMERICAN PHARMACEUTICAL ASSOCIATION AND THE PHARMACEUTICAL PRESS
    - METHOT N; RUBIN J; GUAY D; BEAULIEU C; ETHIER D; REDDY TJ; RIENDEAU D; PERCIVAL MD, J BIOL CHEM, (2007), vol. 282, pages 20836 - 20846
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.